Symbols / HOOK $1.18 +0.00% HOOKIPA Pharma Inc.

Healthcare • Biotechnology • United States • OID
HOOK Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Malte Peters M.D.
Exch · Country OID · United States
Market Cap 14.60M
Enterprise Value -24.73M
Income -73.31M
Sales 9.35M
FCF (ttm) -32.81M
Book/sh 2.71
Cash/sh 3.18
Employees 82
Insider 10d —
IPO Apr 18, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.22
PEG —
P/S 1.56
P/B 0.43
P/C —
EV/EBITDA 0.34
EV/Sales -2.64
Quick Ratio 2.92
Current Ratio 3.61
Debt/Eq 1.75
LT Debt/Eq —
EPS (ttm) -4.83
EPS next Y -5.43
EPS Growth —
Revenue Growth -94.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-05-15
Earnings (prior) 2025-05-15
ROA -45.20%
ROE -105.79%
ROIC —
Gross Margin 0.00%
Oper. Margin -8.85%
Profit Margin 0.00%
Shs Outstand 9.98M
Shs Float 12.34M
Insider Own 0.12%
Instit Own 3.16%
Short Float 0.45%
Short Ratio 0.57
Short Interest 35.80K
52W High 1.77
vs 52W High -33.33%
52W Low 0.81
vs 52W Low 45.50%
Beta 0.83
Impl. Vol. —
Rel Volume 0.11
Avg Volume 11.48K
Volume 1.29K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $1.18
Price $1.18
Change 0.00%
About

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$1.18
Latest analyst target
3. DCF / Fair value
$-59.20
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.18
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-01-10 down HC Wainwright & Co. Buy → Neutral —
2024-12-20 down RBC Capital Outperform → Sector Perform $2
2024-11-21 main JMP Securities Market Outperform → Market Outperform $7
2024-11-15 main RBC Capital Outperform → Outperform $48
2024-08-09 main JMP Securities Market Outperform → Market Outperform $24
2024-07-26 main JMP Securities Market Outperform → Market Outperform $23
2024-06-05 main HC Wainwright & Co. Buy → Buy $6
2024-05-21 reit RBC Capital Outperform → Outperform $5
2024-04-26 main HC Wainwright & Co. Buy → Buy $5
2024-03-25 reit RBC Capital Outperform → Outperform $5
2024-03-25 reit HC Wainwright & Co. Buy → Buy $7
2024-01-30 main RBC Capital Outperform → Outperform $5
2023-09-27 reit RBC Capital Outperform → Outperform $7
2023-09-06 reit Truist Securities Buy → Buy $4
2023-08-11 main HC Wainwright & Co. Buy → Buy $7
2023-06-30 reit RBC Capital Outperform → Outperform $7
2023-06-05 main Morgan Stanley Equal-Weight → Equal-Weight $2
2023-05-12 reit HC Wainwright & Co. Buy → Buy $8
2023-03-20 main Truist Securities — → Buy $4
2023-03-16 reit HC Wainwright & Co. — → Buy $8
News
RSS: Latest HOOK news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-08-19 PETERS MALTE Chief Executive Officer — 25,172 $0.82 $20,684
2025-07-22 COELHO MARY THERESA Chief Financial Officer — 13,609 $0.92 $12,520
2025-07-22 PETERS MALTE Chief Executive Officer — 29,176 $0.92 $26,842
2024-07-22 PETERS MALTE Chief Executive Officer — 108,695 $0.00 $0
2024-07-22 COELHO MARY THERESA Chief Financial Officer — 69,875 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
43.95
+118.32%
20.13
+41.27%
14.25
-22.76%
18.45
Operating Revenue
43.95
+118.32%
20.13
+41.27%
14.25
-22.76%
18.45
Operating Expense
81.34
-13.35%
93.86
+18.09%
79.49
-12.07%
90.40
Research And Development
68.51
-20.73%
86.42
+25.90%
68.64
-17.15%
82.85
Selling General And Administration
20.23
+8.55%
18.63
-0.67%
18.76
+8.63%
17.27
General And Administrative Expense
—
—
18.76
+8.63%
17.27
Other Gand A
—
—
18.76
+8.63%
17.27
Other Operating Expenses
-7.40
+33.92%
-11.19
-41.40%
-7.92
+18.59%
-9.72
Total Expenses
81.34
-13.35%
93.86
+18.09%
79.49
-12.07%
90.40
Operating Income
-37.39
+49.29%
-73.73
-13.02%
-65.24
+9.33%
-71.95
Total Operating Income As Reported
-51.45
+47.33%
-97.69
-33.54%
-73.16
+10.43%
-81.67
EBITDA
-40.85
+47.18%
-77.34
-28.06%
-60.40
+13.88%
-70.13
Normalized EBITDA
-34.19
+47.06%
-64.58
-6.92%
-60.40
+13.88%
-70.13
Reconciled Depreciation
2.75
-22.49%
3.55
-1.39%
3.60
-22.37%
4.64
EBIT
-43.61
+46.09%
-80.89
-26.40%
-64.00
+14.40%
-74.77
Total Unusual Items
-6.67
+47.77%
-12.77
0.00
0.00
Total Unusual Items Excluding Goodwill
-6.67
+47.77%
-12.77
0.00
0.00
Special Income Charges
-6.67
+47.77%
-12.77
0.00
0.00
Restructuring And Mergern Acquisition
2.66
0.00
0.00
—
Write Off
4.00
-68.64%
12.77
0.00
0.00
Net Income
-43.50
+46.67%
-81.58
-25.67%
-64.92
+14.21%
-75.67
Pretax Income
-43.61
+46.30%
-81.21
-25.55%
-64.69
+14.51%
-75.66
Net Non Operating Interest Income Expense
3.70
-25.66%
4.98
+426.00%
0.95
+208.61%
-0.87
Interest Expense Non Operating
0.00
-99.37%
0.32
-53.86%
0.69
-23.50%
0.90
Net Interest Income
3.70
-25.66%
4.98
+426.00%
0.95
+208.61%
-0.87
Interest Expense
0.00
-99.37%
0.32
-53.86%
0.69
-23.50%
0.90
Interest Income Non Operating
3.70
-30.08%
5.29
+224.13%
1.63
+5948.15%
0.03
Interest Income
3.70
-30.08%
5.29
+224.13%
1.63
+5948.15%
0.03
Other Income Expense
-9.92
+20.36%
-12.45
-3076.79%
-0.39
+86.21%
-2.84
Other Non Operating Income Expenses
-3.25
-1138.02%
0.31
+179.85%
-0.39
+86.21%
-2.84
Tax Provision
-0.11
-128.80%
0.37
+60.00%
0.23
+22900.00%
0.00
Tax Rate For Calcs
0.00
-99.05%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
-0.01
+99.50%
-2.68
0.00
0.00
Net Income Including Noncontrolling Interests
-43.50
+46.67%
-81.58
-25.67%
-64.92
+14.21%
-75.67
Net Income From Continuing Operation Net Minority Interest
-43.50
+46.67%
-81.58
-25.67%
-64.92
+14.21%
-75.67
Net Income From Continuing And Discontinued Operation
-43.50
+46.67%
-81.58
-25.67%
-64.92
+14.21%
-75.67
Net Income Continuous Operations
-43.50
+46.67%
-81.58
-25.67%
-64.92
+14.21%
-75.67
Normalized Income
-36.85
+48.46%
-71.49
-10.14%
-64.92
+14.21%
-75.67
Net Income Common Stockholders
-43.50
+46.67%
-81.58
-25.67%
-64.92
+14.21%
-75.67
Diluted EPS
-3.47
+59.79%
-8.63
+12.83%
-9.90
+56.96%
-23.00
Basic EPS
-3.47
+59.79%
-8.63
+12.83%
-9.90
+56.96%
-23.00
Basic Average Shares
12.54
+32.65%
9.45
+44.16%
6.56
-0.02%
6.56
Diluted Average Shares
12.54
+32.65%
9.45
+44.16%
6.56
-0.02%
6.56
Diluted NI Availto Com Stockholders
-43.50
+46.67%
-81.58
-25.67%
-64.92
+14.21%
-75.67
Line Item Trend 2023-12-31
Total Assets
161.34
Current Assets
147.12
Cash Cash Equivalents And Short Term Investments
117.10
Cash And Cash Equivalents
117.10
Receivables
19.27
Accounts Receivable
0.51
Other Receivables
18.76
Prepaid Assets
—
Restricted Cash
0.00
Assets Held For Sale Current
0.00
Other Current Assets
10.75
Total Non Current Assets
14.22
Net PPE
13.21
Gross PPE
23.04
Accumulated Depreciation
-9.82
Properties
0.00
Land And Improvements
2.02
Buildings And Improvements
—
Machinery Furniture Equipment
3.31
Construction In Progress
0.21
Other Properties
14.20
Leases
3.30
Other Non Current Assets
1.01
Total Liabilities Net Minority Interest
71.48
Current Liabilities
41.99
Payables And Accrued Expenses
24.55
Payables
12.87
Accounts Payable
12.50
Current Accrued Expenses
11.68
Pensionand Other Post Retirement Benefit Plans Current
—
Total Tax Payable
0.37
Income Tax Payable
0.37
Current Debt And Capital Lease Obligation
2.76
Current Debt
1.12
Other Current Borrowings
1.12
Current Capital Lease Obligation
1.64
Current Deferred Liabilities
14.68
Current Deferred Revenue
14.68
Total Non Current Liabilities Net Minority Interest
29.49
Long Term Debt And Capital Lease Obligation
3.80
Long Term Debt
—
Long Term Capital Lease Obligation
3.80
Non Current Deferred Liabilities
19.67
Non Current Deferred Revenue
19.67
Other Non Current Liabilities
6.02
Stockholders Equity
89.86
Common Stock Equity
89.86
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
12.05
Ordinary Shares Number
12.05
Treasury Shares Number
0.00
Additional Paid In Capital
467.05
Retained Earnings
-369.26
Gains Losses Not Affecting Retained Earnings
-7.93
Other Equity Adjustments
-7.93
Total Equity Gross Minority Interest
89.86
Total Capitalization
89.86
Working Capital
105.13
Invested Capital
90.98
Total Debt
6.56
Capital Lease Obligations
5.44
Net Tangible Assets
89.86
Tangible Book Value
89.86
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-76.98
-33.82%
-57.52
-187.66%
-20.00
+69.71%
-66.02
Cash Flow From Continuing Operating Activities
-76.98
-33.82%
-57.52
-187.66%
-20.00
+69.71%
-66.02
Net Income From Continuing Operations
-43.50
+46.67%
-81.58
-25.67%
-64.92
+14.21%
-75.67
Depreciation Amortization Depletion
2.75
-22.49%
3.55
-1.39%
3.60
-22.37%
4.64
Depreciation And Amortization
2.75
-22.49%
3.55
-1.39%
3.60
-22.37%
4.64
Other Non Cash Items
—
0.06
-60.00%
0.16
-86.95%
1.23
Stock Based Compensation
2.01
-14.12%
2.35
-53.50%
5.04
-34.03%
7.64
Asset Impairment Charge
4.00
-68.64%
12.77
0.00
0.00
Change In Working Capital
-42.25
-892.76%
5.33
-85.24%
36.11
+1035.33%
-3.86
Change In Receivables
-5.46
-258.19%
3.45
+250.24%
-2.30
-2.73%
-2.24
Changes In Account Receivables
0.52
-91.52%
6.18
+1912.32%
-0.34
+82.45%
-1.94
Change In Prepaid Assets
-5.25
-357.72%
2.04
-16.13%
2.43
+134.28%
-7.09
Change In Payables And Accrued Expense
-2.40
-134.31%
6.99
+1267.71%
0.51
-90.93%
5.63
Change In Accrued Expense
-0.83
-268.98%
0.49
-80.48%
2.51
-47.45%
4.78
Change In Payable
-1.57
-124.16%
6.50
+425.11%
-2.00
-332.98%
0.86
Change In Account Payable
-1.57
-124.16%
6.50
+425.11%
-2.00
-332.98%
0.86
Change In Other Working Capital
-27.54
-233.47%
-8.26
-123.26%
35.51
+2397.05%
1.42
Change In Other Current Assets
—
0.30
-28.30%
0.42
+1.92%
0.42
Change In Other Current Liabilities
-1.59
-243.98%
1.10
+3007.89%
-0.04
+98.10%
-2.00
Investing Cash Flow
-0.19
+95.34%
-4.16
+17.10%
-5.02
+60.12%
-12.58
Cash Flow From Continuing Investing Activities
-0.19
+95.34%
-4.16
+17.10%
-5.02
+60.12%
-12.58
Net PPE Purchase And Sale
-0.19
+95.34%
-4.16
+17.10%
-5.02
+60.12%
-12.58
Purchase Of PPE
-0.19
+95.34%
-4.16
+17.10%
-5.02
+60.12%
-12.58
Capital Expenditure
-0.19
+95.34%
-4.16
+17.10%
-5.02
+60.12%
-12.58
Financing Cash Flow
-1.28
-101.94%
65.67
-9.13%
72.27
+30853.62%
-0.23
Cash Flow From Continuing Financing Activities
-1.28
-101.94%
65.67
-9.13%
72.27
+30853.62%
-0.23
Net Issuance Payments Of Debt
-1.14
+34.95%
-1.75
+38.46%
-2.85
-550.68%
-0.44
Repayment Of Debt
-1.14
+34.95%
-1.75
+38.46%
-2.85
-550.68%
-0.44
Long Term Debt Payments
-1.14
+34.95%
-1.75
+38.46%
-2.85
-550.68%
-0.44
Net Long Term Debt Issuance
-1.14
+34.95%
-1.75
+38.46%
-2.85
-550.68%
-0.44
Net Common Stock Issuance
0.00
-100.00%
49.04
+7.34%
45.69
+22407.88%
0.20
Net Other Financing Charges
-0.14
+9.40%
-0.15
+23.59%
-0.20
—
Changes In Cash
-78.45
-2067.59%
3.99
-91.56%
47.26
+159.95%
-78.83
Effect Of Exchange Rate Changes
0.81
+803.33%
0.09
+112.41%
-0.72
-128.24%
2.57
Beginning Cash Position
117.52
+3.59%
113.44
+69.54%
66.91
-53.27%
143.18
End Cash Position
39.89
-66.06%
117.52
+3.59%
113.44
+69.54%
66.91
Free Cash Flow
-77.17
-25.11%
-61.68
-146.59%
-25.01
+68.17%
-78.60
Interest Paid Supplemental Data
0.00
-85.71%
0.01
-56.25%
0.03
-33.33%
0.05
Income Tax Paid Supplemental Data
0.00
-99.75%
0.40
+40200.00%
0.00
+0.00%
0.00
Common Stock Issuance
0.00
-100.00%
49.04
+7.34%
45.69
+22407.88%
0.20
Issuance Of Capital Stock
0.00
-100.00%
67.57
-10.28%
75.32
+37001.48%
0.20
Net Preferred Stock Issuance
0.00
-100.00%
18.53
-37.45%
29.62
0.00
Preferred Stock Issuance
0.00
-100.00%
18.53
-37.45%
29.62
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category